Ariad Pharmaceuticals, Inc.  

(Public, NASDAQ:ARIA)   Watch this stock  
Find more results for MARTIN R. WILSON
9.71
+0.10 (0.99%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.15 - 9.89
52 week 4.90 - 9.89
Open 9.65
Vol / Avg. 5.51M/5.30M
Mkt cap 1.82B
P/E     -
Div/yield     -
EPS -0.87
Shares 187.29M
Beta 1.39
Inst. own 71%
Jun 25, 2015
ARIAD Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
May 7, 2015
Q1 2015 ARIAD Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
May 7, 2015
Q1 2015 ARIAD Pharmaceuticals Inc Earnings Call - 8:30AM EDT - Add to calendar
Mar 2, 2015
ARIAD Pharmaceuticals Inc at Cowen Health Care Conference
Feb 25, 2015
ARIAD Pharmaceuticals Inc at RBC Healthcare Conference
Feb 19, 2015
Q4 2014 ARIAD Pharmaceuticals Inc Earnings Release
Feb 19, 2015
Q4 2014 ARIAD Pharmaceuticals Inc Earnings Call - Webcast
Feb 12, 2015
ARIAD Pharmaceuticals Inc at Leerink Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -8.60% -154.25%
Operating margin -10.68% -151.97%
EBITD margin - -143.61%
Return on average assets -4.24% -33.36%
Return on average equity -28.50% -122.11%
Employees 379 -
CDP Score - -

Address

26 LANDSDOWNE ST
CAMBRIDGE, MA 2139
United States - Map
+1-617-4940400 (Phone)
+1-617-4948144 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ARIAD Pharmaceuticals, Inc. is a global oncology company engaged in the discovery, development and commercialization of medicines for the cancer patients. The Company�s products that include Iclusig (ponatinib), AP26113 and ridaforolimus, were discovered based on computational and structure-based drug design. Iclusig is known to demonstrate activity against the T315I gatekeeper mutation of BCR-ABL, the most common mutation occurring in approximately 10% of patients with drug resistance. AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin, or mTOR, that the Company discovered and developed internally.

Officers and directors

Harvey J. Berger M.D. Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Edward M. Fitzgerald Chief Financial Officer, Executive Vice President, Treasurer
Age: 59
Bio & Compensation  - Reuters
Martin J. Duvall Executive Vice President, Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
David L. Berstein Esq. Senior Vice President, General Counsel and Chief Intellectual Property Counsel, and Secretary
Age: 62
Bio & Compensation  - Reuters
Maria E. Cantor Senior Vice President - Corporate Affairs and Human Resources
Age: 46
Bio & Compensation  - Reuters
Daniel M. Bollag Ph.D. Senior Vice President - Regulatory Affairs and Quality
Age: 53
Bio & Compensation  - Reuters
Hugh M. Cole Senior Vice President, Chief Business Officer
Age: 49
Bio & Compensation  - Reuters
Frank G. Haluska M.D., Ph.D. Senior Vice President - Clinical Research and Development and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Timothy P. Clackson Ph.D. President - Research and Development, Chief Scientific Officer
Age: 49
Bio & Compensation  - Reuters
Wayne R. Wilson Lead Independent Director
Age: 66
Bio & Compensation  - Reuters